Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.

•Anlotinib is effective in the third-line treatment or beyond for advanced non-small cell lung cancer.•Anlotinib improved quality of life in advanced non-small cell lung cancer patients.•Anlotinib is a choice for the third-line treatment or beyond in advanced non-small cell lung cancer.